<DOC>
	<DOCNO>NCT00555893</DOCNO>
	<brief_summary>This study randomize , blind , placebo-controlled clinical efficacy trial ass duration severity influenza symptom , duration viral shedding , influenza patient receive oseltamivir early late relative placebo . There two main hypothesis study : 1 . The duration influenza symptom , mean severity score , duration viral shed reduced patient initiate oseltamivir treatment late ( 48 119 hour ) compare receive antiviral therapy . 2 . Prior influenza vaccination ( season ) reduce duration influenza symptom mean symptom severity patient receive oseltamivir adjust age time antiviral therapy ( early versus late ) . There two secondary hypothesis : 1 . The duration influenza symptom , mean severity score , duration viral shed reduced patient influenza initiate oseltamivir treatment early ( &lt; 48 hour ) versus late ( 48 119 hour ) . 2 . The incidence secondary complication low patient initiate oseltamivir therapy late relative receive antiviral therapy .</brief_summary>
	<brief_title>Efficacy Study Early Versus Late Oseltamivir Administration Treating Preventing Influenza</brief_title>
	<detailed_description>In past decade influenza become increasingly recognize serious disease pandemic threat . Elderly person , young child , individual chronic medical condition great risk complication death influenza infection . Neuraminidase inhibitor currently license treatment prevention influenza start early course illness , little known regard effect oseltamivir ( one neuraminidase inhibitor ) illness severity initiate later course illness . Greater knowledge treatment effect urgently need optimal management seasonal influenza , maximize use limited stockpile antiviral drug event influenza pandemic .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Inclusion criterion : 1 . Outpatient inpatient encounter acute respiratory illness le 5 day ( 120 hour ) duration . 2 . Acute respiratory illness feverishness OR cough . 3 . Access internet telephone home . This required symptom severity report submit twice daily use either secure webbased form automate telephone entry . All phone Marshfield area touchtone service , allow automate data entry . Exclusion criterion : 1 . Institutional resident ( include assist living skilled nursing facility ) . 2 . Selfreported chronic liver kidney disease . These condition list precaution oseltamivir manufacturer package insert ( www.rocheusa.com/products/tamiflu/pi.pdf ) . 3 . Pregnancy breastfeed . Oseltamivir classify pregnancy category C , excrete breast milk . The package insert state drug use potential benefit justifies potential risk fetus breastfed infant . 4 . Prior hypersensitivity reaction oseltamivir . 5 . Dementia , impaired communication , reason inability provide inform consent . 6 . Immunocompromised status , include HIV infection , neutropenia , systemic corticosteroid use , use immunosuppressive drug past 30 day . The manufacturer state efficacy oseltamivir establish immunocompromised patient . 7 . Patient receive 1 dos influenza antiviral agent ( oseltamivir , zanamivir , amantadine , rimantadine ) prescription one drug prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>randomize</keyword>
	<keyword>blind</keyword>
	<keyword>control</keyword>
	<keyword>efficacy</keyword>
</DOC>